Posters for 2026 britMODIS

Introduction Our movement disorder service provides care for people living with Parkinson’s across 4 boroughs and 2 acute hospitals. There are predicted to be 1,671 people living with Parkinson’s in our area1. Foslevodopa-foscarbidopa is indicated for the treatment of advanced levodopa-responsive Parkinson’s with severe motor fluctuations when available combinations of medications have not given satisfactory results and apomorphine or deep brain stimulation (DBS) are no longer effective or not appropriate2. Method Our service aims to proactively identify patients who are living with advance

Background: Falls are a serious concern for people with Parkinson’s disease (PD), often leading to hospitalisation, dependence and reduced quality of life. Effective fall management requires identification of those at risk. Although many clinical and mobility-related outcomes have been linked with falls, it remains unclear which selection of outcomes best discriminate fallers from non-fallers. Methods: Participants with PD were recruited as part of the ICICLE-GAIT study. Data presented are from the 54-month and 72-month follow-up. Participants were stratified into fallers and non-fallers based

Introduction: People living with advanced Parkinson’s Disease (PD) and Atypical Parkinsonian Syndromes (APS) often experience reduced mobility. This may result in difficulty attending specialist outpatient clinics, and consequently reduced access to review potentially complex symptoms. Therefore, there is a potential unmet need for people living with these conditions to have ongoing specialist medical input in community settings. Objectives: To record common interventions and outcomes following a Parkinson’s Disease Fellow Home visit. Method: People identified for a Home visit by a PD Multi

Background Parkinson's disease (PD) is recognized as one of the most prevalent neurological disorders globally [1]. Despite its widespread incidence, there remains a significant gap in the understanding of PD, particularly concerning its risk factors [2]. We set out to catalogue the risk factors patients with Parkinson’s Disease (PD) are exposed to. The Transforming Parkinson’s Care in Africa (TraPCAf) initiative is a collaborative research effort, which aims to address various facets of PD [3]. Multiple risk factors for PD have been established across various regions of the world. Newer

Background Parkinson’s disease (PD) results in a 2-to-4-fold higher risk of hip and fragility fractures due to osteoporosis, falls, and motor dysfunction. Fractures in this group often cause loss of mobility, extended admissions, and higher mortality. Despite these consequences, bone-health assessment is inconsistently incorporated into routine PD care. Introduction The local analysis of 100 patients at York Hospital during the 2025 Parkinson’s UK audit, revealed bone health was considered in 10% of cases, compared with a national figure of 63% (2022 data for comparable services; p < 0.001)

Introduction Patients with Parkinson’s Disease (PD) frequently experience delays or missed doses of time-critical medications, leading to worsened symptoms and prolonged stays. This issue is thought to be partly due to gaps in doctors’ knowledge and prescribing practices. Therefore, this project uses a survey to assess staff knowledge and practices and identify gaps in managing Parkinson’s medications in acute and complex clinical scenarios. Methods: A questionnaire was distributed to 26 doctors across adult medical wards and the Emergency Department, including consultants and trainees. The

Introduction: Parkinson’s UK consistently report that over half of inpatients with Parkinson’s face challenges getting their medications on time. This is associated with patient harm, poorer outcomes and increased admission length. Although electronic prescribing has benefits, it has not solved these issues. We audited local practice and implemented an EPMA care plan to improve reliability. Method: A two-cycle clinical audit in a central London teaching hospital. Cycle 1 (n=29) and cycle 2 (n=23) reviewed electronic records over two 4-month periods for inpatients with Parkinson’s disease

Background: Diagnosing Parkinsonism remains a common and clinically significant challenge within movement disorder services, particularly in early disease and in atypical or non-motor–predominant presentations. Dopamine transporter (DAT) imaging is recommended by NICE where diagnostic uncertainty persists; however, real-world evidence demonstrating its impact on clinical decision-making beyond diagnostic confirmation remains limited. Methods: We conducted a retrospective audit of all DAT scans requested within a UK specialist movement disorder service between January 2023 and December 2024

Introduction The Personal Kinetograph™ (PKG) is a remote monitoring device that provides objective evidence of motor control in Parkinson's disease (PD). It is conditionally recommended by NICE to aid clinical decision-making (1). Our hospital trust has developed a PKG service over two years. We present the results of patient questionnaires to demonstrate the role of PKG in patient education and mental wellbeing, alongside clinical care. Method Between August 2023-December 2025, 40 patients under the care of Geriatrics Parkinson's Team underwent PKG monitoring. Results were explained via

Introduction Within the Older Person’s Medicine Movement Disorder service at Newcastle upon Tyne Hospitals, we were aware people with Parkinson's (PWP) living in nursing care were not necessarily receiving the same quality of care as other PWP. We have developed a nursing home movement disorder clinic to address this. Methods Practically, approximately 15% of PWP were identified as living in nursing care. After review of the geography and numbers, one consultant and specialist nurse clinic were allocated a month to facilitate care home visits to all PWP within 6 months. After identifying PWP

Introduction Parkinson’s disease dementia (PDD) is characterised by years of motor symptoms preceding cognitive decline, particularly presenting with declining executive function, attention, visuospatial abilities, and psychiatric symptoms. The motor symptoms of Parkinson’s disease are managed under a Parkinson’s and movement disorder service led by geriatricians or neurologists and should involve a multidisciplinary team. When dementia symptoms develop, patients are generally referred to a memory service led by old age psychiatrists with dementia support advisors and admiral nurses available

Aims/Purpose: To assess the barriers and facilitators for rehabilitation in the older Parkinson’s Disease (PD) patient population that have been admitted to Great Western Hospital (GWH); as viewed by clinicians who work within the acute inpatient setting. This was accomplished through an internal service evaluation project designed to create a GWH-specific action plan, which may also have broader applicability. Methods: A review of the related literature informed the development of interview questions, which guided 20 semi-structured interviews with clinicians conducted in collaboration with

Introduction: Foslevodopa-foscarbidopa (Produodopa) is a new subcutaneous infusion run continuously over 24 hours for people with Parkinson’s (PwP). Foslevodopa is a prodrug for levodopa, the most effective treatment for Parkinson’s symptoms. Studies demonstrate that Produodopa improves symptom fluctuations (i.e. less OFF time & less troublesome dyskinesia) compared to oral medications. Gait and balance impairment are key risk factors for falls in advanced Parkinson’s and are less levodopa responsive. However, the impact of Produodopa on gait and balance has not yet been described. Methods

Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by postural instability, vertical supranuclear gaze palsy, bradykinesia, extrapyramidal rigidity and dementia. Patients with PSP lose independent gait and ability to stand unassisted, often becoming wheelchair-bound within 1-3 years. Clinically recognized PSP movement features, including tendency to fall backwards, posterior weight distribution and a toe-up maneuver with weight shift to the heels in sit-to-stand transitions, have been used to track progression and consider physiotherapy needs

Introduction: Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide and is often associated with frailty and sarcopenia. The cardinal motor features include bradykinesia, rest tremor, rigidity and postural instability. In low-resource settings such as Tanzania and sub-Saharan Africa (SSA), data on motor burden and physical function in PD are limited. Aims: To assess motor symptom burden and physical function in people with Parkinson's disease (PwP) in northern Tanzania. Methods: A cross-sectional study was conducted involving 28 PwP in the Hai district of

Background: Cognitive impairment (CI) is a common non-motor symptom of Parkinson’s Disease (PD), but little is known about its profile and assessment in Sub-Saharan Africa (SSA). This study aims to characterise cognitive function in a cohort of people with PD (PwP) in northern Tanzania, and evaluate the feasibility and acceptability of cognitive screening tools in a low-resource, community setting. Methods: Twenty-eight PwP identified in a previous door-to-door survey were followed up. Cognitive function was assessed using the Identification and Intervention for Dementia in Elderly Africans

Introduction There are few data on Parkinson’s disease (PD) in Africa, particularly in sub-Saharan Africa (SSA). The NIHR Global Health Research Group Transforming Parkinson’s Care in Africa (TraPCAf) is a four-year study, running from September 2022, investigating PD in seven African countries (1). In SSA, hypertension is highly prevalent, with many individuals remaining undiagnosed and, among those diagnosed, many untreated or poorly controlled (2). Method The TraPCAf project is recruiting a target of 1,000 people with PD (PwP) and 2,000 age- and sex-matched healthy controls. Data collected

Objective: Guidelines recommend use of rotigotine patches as an option if Parkinson’s patients are unable to take their usual oral medication, but this strategy has not been tested in clinical trials. We audited outcomes for such patients in a large UK teaching hospital. Background: This project was undertaken at University Hospitals of Derby and Burton. Method: In this retrospective study, data was extracted from the hospital’s electronic prescribing and medication administration system, Lorenzo. We examined data on every hospitalised Parkinson’s patient prescribed rotigotine at Royal Derby

Introduction: The Lewy Body Dementias (LBD) incorporate both Parkinson’s Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB). These conditions have a heterogeneous presentation and disease trajectory with much inter-individual variability. Accurate diagnostics and prognostication are becoming increasingly important in the potential disease modifying era. Cardiovascular autonomic dysfunction is a supportive diagnostic feature of DLB and a well-known non-motor phenotype of Parkinson’s Disease. It most commonly presents with orthostatic hypotension (OH) which can be easily measure

Introduction: Dysphagia in Parkinson’s disease (PD) increases the risk of aspiration pneumonia and medication harm during acute admissions. When patients are made nil by mouth (NBM), time critical PD medicines may be delayed while clinicians calculate levodopa equivalent dose (LED) and convert to alternative formulations. We introduced a patient held Dysphagia Alert Card to provide a specialist approved emergency prescribing plan and improve timely prescribing and review. Method: Patients with established dysphagia or high risk were identified during routine specialist reviews and inpatient